ClinicalTrials.gg
RecruitingNCT06013618Updated Jun 17, 2025

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

A Phase 2 interventional study of Naxitamab monotherapy and GM-CSF in Neuroblastoma, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 12 Months and older. Per ClinicalTrials.gov, last updated 2025-06-17.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
12 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing naxitamab in Neuroblastoma — 9 open to participants now, 12 under way, none of them phase 3. naxitamab · Neuroblastoma.

Planned enrollment
3rd of 17
120 · median 62
Started
2023
with 1 other
Phase 2
11 of 17
7 open now
Primary completion
2026-12
later than 2 of 11 live
Registered
11th of 17
by date
Lead sponsor
1 of 17
Sun Yat-sen University

Among the 17 studies testing naxitamab in Neuroblastoma, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2023, is one of 11 in phase 2, reaches primary completion later than 2 of the 11 other live ones, and was the 11th registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

9 of the 17 studies testing naxitamab in Neuroblastoma are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About naxitamab

naxitamab: first FDA approval 2020 (DANYELZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: 12 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing naxitamab in Neuroblastoma, or all of them as a file.
02

Study summary

This is an prospective study to evaluate the safety and efficacy of naxitamab monotherapy or combined with chemotherapy or combined with chemotherapy and checkpoint inhibitor in the treatment of pediatric high-risk and refractory/relapsed neuroblastoma in Sun Yat-sen University Cancer Center.

Read the detailed description

Patients with high risk neuroblastoma who obtain CR after chemotherapy combined with surgery, radiotherapy and/or hematopoietic stem cell transplantation received axitamab and GM-CSF. Patients with high-risk neuroblastoma treated by chemotherapy combined with surgery, radiotherapy and or hematopoietic stem cell transplantation patients with tumor residual or progression during treatment (refractory) received naxitamab and GM-CSF in combination with irinotecan and temozolomide or naxitamab and GM-CSF in combination with irinotecan and temozolomide and PD-1 antibody.

03

Conditions studied

  • Neuroblastoma

Browse trials for

04

Who can participate

Ages eligible
12 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1)Confirmed diagnosis of high-risk NB 2)1 year of age or above 3)Patient or parent/guardian must provide written to participate 4)If patient is sexually active, the patient agrees to use effective 5)Confirmed negative urine pregnancy test for sexually active female of (post-menarche)

Exclusion criteria

Exclusion Criteria:

  1. Significant organ toxicity
  2. Known or suspected allergy or to anti-GD2 antibodies or to GM-CSF or its s components.
  3. Patient is pregnant, planning to become pregnant (while being treated with naxitamab) or is currently breastfeeding
  4. Patient will undergo treatment with another drug, whilst being treated with naxitamab or has received another investigational drug within the 4 weeks prior to commencing treatment with naxitamab
  5. Patient is either eligible and able to participate in or is currently participating in an active interventional Y-mAbs sponsored clinical trial with naxitamab within the indication applied for
  6. Patient is unable to comply with the naxitamab treatment or has a medical condition that would potentially increase the severity of the toxicities experienced from naxitamab treatment at the discretion of the treating physician
  7. of \<50% by echocardiography OR other cardiac disorders at the discretion of the investigator
  8. Inadequate pulmonary function defined as evidence of dyspnea at rest, exercise intolerance, and/or chronic oxygen requirement. In addition, room air pulse oximetry \< 94% and/or abnormal pulmonary function tests if these assessments are clinically indicated

    Applicable for treatment with naxitamab in combination with GM-CSF only:

  9. Patient has active progression of the NB disease
  10. Patient has active NB disease at primary site or soft-tissue
  11. Patient has known when initiating naxitamab treatment
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Other
    naxitamab and GM-CSF only

    Suitable for patients with high risk neuroblastoma who obtain CR after chemotherapy combined with surgery, radiotherapy and/or hematopoietic stem cell transplantation. The treatment cycle is repeated every 4 weeks for a total of 5 courses, and discontinuation of nasetuzumab and GM-CSF should be considered if disease progression or unacceptable toxicity occurs.

    Drug: Naxitamab monotherapy · Drug: GM-CSF

  • Other
    naxitamab and GM-CSF in combination with irinotecan and temozolomide

    Suitable for high-risk group neuroblastoma treated by chemotherapy combined with surgery, radiotherapy and or hematopoietic stem cell transplantation patients with tumor residual or progression during treatment (refractory); Patients who relapse after initial treatment. Repeat every 3 weeks until tumor progression, patient withdrawal, or toxicity becomes intolerable, up to 8 procedures.

    Drug: Irinotecan · Drug: Temozolomide · Drug: Naxitamab in combination therapy · Drug: GM-CSF with combination regimen

  • Other
    naxitamab and GM-CSF in combination with irinotecan and temozolomide and PD-1 antibody

    Suitable for high-risk group neuroblastoma treated by chemotherapy combined with surgery, radiotherapy and or hematopoietic stem cell transplantation patients with tumor residual or progression during treatment (refractory); Patients who relapse after initial treatment. Repeat every 3 weeks until tumor progression, patient withdrawal, or toxicity becomes intolerable, up to 8 procedures.

    Drug: Irinotecan · Drug: Temozolomide · Drug: Naxitamab in combination therapy · Drug: GM-CSF with combination regimen · Drug: Sintilimab

Interventions

  • DrugNaxitamab monotherapy

    Naxitamab is administered on days 1, 3, and 5

    Also known as: hu3F8

  • DrugGranulocyte-Macrophage Colony-Stimulating FactorStudies of Granulocyte-Macrophage Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating Factor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Each treatment cycle is 28 days and is started with five days (days -4 to 0) of GM-CSF administered at 250 mcg/m2/day in advance of the start of naxitamab infusion. GM-CSF is thereafter administered at 500 mcg/m2/day on days 1 to 5.

    Also known as: Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor

  • Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.

    Also known as: DNA topoisomerase I inhibitor

  • Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.

    Also known as: Temozolomide for Injection

  • DrugNaxitamab in combination therapy

    Drug page: NaxitamabStudies of NaxitamabNaxitamab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Naxitamab 2.25mg/kg IV will be administered on Days 2, 4, 8 and 10.

    Also known as: hu3F8

  • DrugGM-CSF with combination regimen

    GM-CSF 250 mcg/m2/day will be administered subcutaneously on Days 6-10.

    Also known as: Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor

  • Sintilimab was administerd with 3mg/kg (max 200mg) on day 11 every 3 weeks.

    Also known as: PD-1 antibody

06

What researchers measure

Primary outcomes

  1. ORR

    The proportion of patients who achieved CR or PR

    Time frame: from start of naxitamab treatment to 1.5 years after EOT

Secondary outcomes

  1. DCR

    The proportion of patients who achieved CR or PR or SD

    Time frame: from start of naxitamab treatment to 1.5 years after EOT

  2. EFS

    The time from from start of naxitamab treatment to disease progression, recurrence

    Time frame: from start of naxitamab treatment to 1.5 years after EOT

  3. OS

    The time from from start of naxitamab treatment to death or loss of follow-up

    Time frame: from start of naxitamab treatment to 1.5 years after EOT

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.

Of 62 non-industry phase 2 interventional studies under Neuroblastoma, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 99. This study's planned 42 months is below that.

Counting every sponsor, half of 67 studies reached it within 74 months; a quarter within 52 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2023
First posted
Aug 28, 2023
StartActual
Jun 19, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Jun 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06013618
Collaborators
Hainan General Hospital
Responsible party
Yizhuo Zhang (Director, Sun Yat-sen University) — Principal investigator
First posted
Aug 28, 2023
Start date
Jun 19, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 17, 2025

Study contacts

Yizhuo Zhang, MD
Contact
zhangyzh@sysucc.org.cn
0087342460
Juan Wang
Contact
wangjuan@sysucc.org.cn
008687342660
Yizhuo Zhang
study chair · SunYat Sen University Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naxitamab

Start the discussion